"The highly qualified physicians and staff at Pacific Cancer Care work diligently to provide our patients & family members with a comfortable and caring environment while delivering high quality personalized care. Everything we do at PCC is designed with our patients' in mind."
Top Sponsors
Top Collaborators
Trials By Phase
Recruitment Status
Top Conditions
Intervention Types
Top Intervention Names
Trials By Gender
Lead Sponsor
# Trials
Eli Lilly and Company
5
SWOG Cancer Research Network
5
Oncotherapeutics
4
Bristol-Myers Squibb
2
Celgene
2
Daiichi Sankyo, Inc.
2
Dana-Farber Cancer Institute
2
National Cancer Institute (NCI)
2
Amgen
1
Aptose Biosciences Inc.
1
Astellas Pharma Global Development, Inc.
1
Clinical Trials at Pacific Cancer Care
During the past decade, Pacific Cancer Care conducted 18 clinical trials. In the 10-year time frame, 18 clinical trials started and 16 clinical trials were completed, i.e. on
average, 88.9% percent of trials that started reached the finish line to date. In the past 5 years, 4 clinical trials started and 8 clinical trials were completed. i.e. 200%
of trials that started reached the finish line.
Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer
2011-05-01
2015-12-01
Completed
160
Clinical Trials Sponsors and Collaborators
Out of the total clinical trials conducted in "Pacific Cancer Care" #1 sponsor was "Eli Lilly and Company" with 5 trials, followed by "SWOG Cancer Research Network" with 5 trials
sponsored, "Oncotherapeutics" with 4 trials sponsored, "Bristol-Myers Squibb" with 2 trials sponsored and "Celgene"
with 2 trials sponsored. Other sponsors include 21 different institutions and
companies that sponsored additional 28 trials in total.
In terms of collaborators to trials, out of the total clinical trials conducted in "Pacific Cancer Care"
#1 collaborator was "National Cancer Institute (NCI)" with 5 trials as a collaborator, "AstraZeneca" with 2 trials as a collaborator, "Blood Cancer Research Partnership" with 2 trials as a collaborator, "The Leukemia and Lymphoma Society" with 2 trials as a collaborator and "Academic GI Cancer Consortium (AGICC)" with 1 trials as a collaborator. Other collaborators include 8 different institutions and companies that were
collaborators in the rest 18 trials.
Clinical Trials Conditions at Pacific Cancer Care
According to Clinical.Site data, the most researched conditions in "Pacific Cancer Care" are
"Multiple Myeloma" (9 trials), "Recurrent Squamous Cell Lung Carcinoma" (5 trials), "Breast Cancer" (4 trials), "Stage IV Squamous Cell Lung Carcinoma AJCC v7" (4 trials) and "Metastatic Breast Cancer" (3 trials). Many other conditions were trialed in "Pacific Cancer Care" in a lesser frequency.
Clinical Trials Intervention Types at Pacific Cancer Care
Most popular intervention types in "Pacific Cancer Care" are "Drug" (39 trials), "Other" (8 trials), "Biological" (4 trials), "Procedure" (2 trials) and "Behavioral" (1 trials). Other intervention types were less common.
The name of intervention was led by "Laboratory Biomarker Analysis" (6 trials), "Abemaciclib" (4 trials), "Dexamethasone" (4 trials), "Nivolumab" (4 trials) and "Palbociclib" (4 trials). Other intervention names were less common.
Clinical Trials Genders at Pacific Cancer Care
The vast majority of trials in "Pacific Cancer Care" are
39 trials for "All" genders, 3 trials for "Female" genders and 2 trials for "Male" genders.
Clinical Trials Status at Pacific Cancer Care
Currently, there are NaN active trials in "Pacific Cancer Care".
undefined are not yet recruiting,
7 are recruiting,
12 are Active, not recruiting,
and undefined are Enrolling by invitation.
In total, there were 12 completed trials in Pacific Cancer Care,
undefined suspended trials,
and 7 terminated clinical trials to date.
Out of the total trials that were conducted in Pacific Cancer Care, 9 "Phase 1"
clinical trials were conducted, 20 "Phase 2" clinical
trials and 16 "Phase 3" clinical trials were conducted as
well. "Phase 4" trials included 1 trials, and there were
also 1 trials that are defined as “Not Applicable".